Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: A randomized controlled trial

Diabetes Care

Volumn 39, Issue 12, 2016, Pages 2211-2217

  Timmers, Silvie ^a   De Ligt, Marlies ^a   Phielix, Esther ^a   Van De Weijer, Tineke ^a   Hansen, Jan ^a   Moonen Kornips, Esther ^a   Schaart, Gert ^a   Kunz, Iris ^b   Hesselink, Matthijs K C ^a   Schrauwen Hinderling, Vera B ^a   Schrauwen, Patrick ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; RESVERATROL; ANTIDIABETIC AGENT; DIHYDRORESVERATROL; GLUCOSE BLOOD LEVEL; INSULIN; STILBENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATTY ACID OXIDATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN SENSITIVITY; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; MITOCHONDRIAL RESPIRATION; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; STILBENES;

EID: 85006086219     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0499     Document Type: Article

References (36)

1. Cantó C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009;20: 98-105
2. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1a, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 2011;93:884S-890S
3. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127: 1109-1122
4. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-196
5. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006;5:493-506
6. Timmers S, Hesselink MK, Schrauwen P. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci 2013;1290:83-89
7. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342
8. Burgess TA, Robich MP, Chu LM, Bianchi C, Sellke FW. Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg 2011; 146:556-564
9. Marchal J, Blanc S, Epelbaum J, Aujard F, Pifferi F. Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS One 2012;7:e34289
10. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612-622
11. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012;67:1307-1312
12. Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2092-2103.e1, 6
13. Dash S, Xiao C, Morgantini C, Szeto L, Lewis GF. High-dose resveratrol treatment for 2weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol 2013;33:2895-2901
14. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186-1195
15. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011;106: 383-389
16. Elliott PJ,Walpole S, Morelli L, et al. Resveratrol/SRT-501. Drugs Future 2009;34:291-295
17. Movahed A, Nabipour I, Lieben Louis X, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013;2013:851267
18. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012;32:537-541
19. Snedecor GW, Cochran WG. Statistical Methods. Ames, Iowa State University Press, 1980
20. Bilet L, Brouwers B, van Ewijk PA, et al. Acute exercise does not decrease liver fat in men with overweight or NAFLD. Sci Rep 2015; 5:9709
21. Lindeboom L, Nabuurs CI, Hesselink MK, Wildberger JE, Schrauwen P, Schrauwen-Hinderling VB. Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein. Am J Clin Nutr 2015;101:65-71
22. Guiu B, Petit JM, Loffroy R, et al. Quantification of liver fat content: comparison of tripleecho chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009;250:95-102
23. Schoffelen PF, Westerterp KR, Saris WH, Ten Hoor F. A dual-respiration chamber system with automated calibration. J Appl Physiol (1985) 1997;83:2064-2072
24. Phielix E, Schrauwen-Hinderling VB, Mensink M, et al. Lower intrinsic ADPstimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes 2008;57: 2943-2949
25. Koopman R, Schaart G, Hesselink MK. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol 2001;116:63-68
26. van de Weijer T, Phielix E, Bilet L, et al. Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes 2015;64:1193-1201
27. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959;82:420-430
28. Meex RC, Schrauwen-Hinderling VB, Moonen-Kornips E, et al. Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 2010; 59:572-579
29. Pocock S. Clinical Trials: A Practical Approach. Chichester, John Wiley and Sons, 1987
30. Fryer LG, Parbu-Patel A, Carling D. The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226-25232
31. Maratos-Flier E. Metabolic disease puts up a fight: microbes, metabolism and medications. Nat Med 2013;19:1218-1219
32. Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol 2014;80:5935-5943
33. Bode LM, Bunzel D, Huch M, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr 2013;97: 295-309
34. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15:675-690
35. Thazhath SS, Wu T, Bound MJ, et al. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial. Am J Clin Nutr 2016;103:66-70
36. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: A metaanalysis of randomized controlled trials. Clin Nutr 2015;34:27-34